Aroa Biosurgery Ltd (ARX)

Snapshot

ARX's Principal Activity is the the development, manufacture and distribution of products to improve the healing in complex wounds and soft tissue reconstruction.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Ms Tracy Weimar	Joint Company Secretary	Jul 2020
Mr John Flower Diddams	Non-Executive Director	Nov 2019	Mr John Flower Diddams Non-Executive Director Mr Diddams has over forty years' experience as a CFO, CEO and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations' law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors. John is currently a non-executive director of New Zealand based Volpara Health Technologies Limited (ASX:VHT) and Surf Lakes Holdings Limited. He is also Chair of the Risk Committee of the company.
Mr Steven (Steve) Barnard Engle	Non-Executive Director	Apr 2015	Mr Steven (Steve) Barnard Engle Non-Executive Director Mr Engle has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic and infectious disease areas. He is the Chief Executive Officer of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Steven served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Steven served as Chairman and CEO of La Jolla Pharmaceutical Company. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation. Steven is the non-executive Chairman of the Board of Prescient Therapeutics Ltd., an ASX listed clinical stage oncology company, and a director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a Member of the board of the Lupus Foundation of America.
Mr John Richard Pinion II	Non-Executive Director	Feb 2015	Mr John Richard Pinion II Non-Executive Director Mr Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical Development and QC. In the ten years prior to joining Ultragenyx, John has held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is also member of the Risk Committee of the company.
Mr James (Jim) Neil McLean	Non-Executive Chairman,Non-Executive Director	Aug 2011	Mr James (Jim) Neil McLean Non-Executive Chairman,Non-Executive Director Mr McLean has gained 25 years experience serving as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa, current appointments include Chair of Prevar Limited, R J Hill Laboratories Limited and Information Tools Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing. Before focusing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office. He is a member of the Risk Committee.
Mr Philip John McCaw	Non-Executive Director	Mar 2008	Mr Philip John McCaw Non-Executive Director Mr McCaw is the Founding Partner of Movac, one of New Zealand's Venture Capital funds. Phil has over 20-years experience investing into New Zealand technology companies and helping to guide their growth. Phil was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. He was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is a advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand; a founding investor in the Lightning Lab technology accelerator; and a founding investor in the Kiwi Landing Pad in San Francisco. Prior to starting Movac Phil spent 10-years with Deloitte Consulting working in New Zealand and the USA.
Mr Brian Roderick Ward	Chief Executive Officer,Managing Director	Sep 2007	Mr Brian Roderick Ward Chief Executive Officer,Managing Director Mr Ward has held senior corporate roles in life sciences and health care companies over the last 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels.
Mr James Blair Agnew	Chief Financial Officer,Joint Company Secretary	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
19/08/21	James (Jim) McLean	Buy	+102,400	$0.75	$76,800	Exercise of options
19/08/21	James (Jim) McLean	Exercise	102,400	$0.75	$76,800	Exercise of options
06/08/21	Philip McCaw	Transfer	2,864,879	$1.151	$3,298,621	Off-market transfer
11/06/21	Philip McCaw	Buy	+81,925	$0.75	$61,443	Exercise of options
11/06/21	Philip McCaw	Exercise	81,925	$0.75	$61,443	Exercise of options
22/02/21	John Diddams	Sell	+200,000	$1.193	($238,680)	On-market trade
09/12/20	John Diddams	Buy	+165,000	$0.107	$17,737	Exercise of options
09/12/20	John Diddams	Exercise	165,000	$0.107	$17,737	Exercise of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
James (Jim) McLean	19/08/2021	2,674,708	N/A	204,800	N/A
Philip McCaw	06/08/2021	N/A	19,669,229	163,850	N/A
Brian Ward	31/03/2021	N/A	N/A	3,132,525	N/A
John Pinion II	31/03/2021	N/A	N/A	879,000	N/A
Steven (Steve) Engle	31/03/2021	N/A	N/A	879,000	N/A
John Diddams	31/03/2021	N/A	N/A	330,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Mark Ritcher (Ritcher Investments A/C)	200,890,889	1.37%
Mr Brian Ward & Mrs Tracey Ward (Arawai No 2 A/C)	33,125,800	11.02%
Movac Fund 3 Lp	18,679,050	6.21%
Citicorp Nominees Pty Limited	17,856,411	5.94%
Phil Mccaw (Mcsyth Capital Investment A/C)	16,722,425	5.56%
National Nominees Limited	16,075,659	5.35%
J P Morgan Nominees Australia Pty Limited	13,774,374	4.58%
Richard Abbott (Jester 002 Investment A/C)	11,579,775	3.85%
Hsbc Custody Nominees (Australia) Limited	8,293,333	2.76%
Washington H Soul Pattinson And Company Limited	7,499,800	2.49%
Aspire Nz Seed Fund Ltd	7,491,000	2.49%
Sparkbox Investments Ltd	7,312,050	2.43%
K One W One (No 3) Ltd	5,882,550	1.96%
Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C)	5,051,704	1.68%
Bnp Paribas Noms Pty Ltd (Drp)	4,835,542	1.61%
Bnp Paribas Noms Pty Ltd (Drp) I	4,819,950	1.60%
Sharon Bryant (Ot Investment A/C)	4,815,198	1.60%
Mesynthes Nominees Ltd20	4,580,250	1.52%
Custodial Services Limited (Beneficiaries Holding A/C)	4,120,200	1.37%
Nancy Yopp	3,913,842	1.30%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2018	$0.30	29 June
2017	$0.515	28 June
2016	$0.45	28 June
2015	$0.001	30 June
2014	$0.003	30 June

ARX Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.